89bio shares maintain Buy rating as analyst cites confidence in pegozafermin trial outcomes
H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.
89bio’s Promising Drug Developments and Stable Financial Outlook Justify Buy Rating
(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C.
89bio’s (ETNB) “Sell (D-)” Rating Reiterated at Weiss Ratings
Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...
89bio's chief technical operations officer sells $71,149 in stock
Nguyen Quoc, the Chief Technical Operations Officer at 89bio, Inc. (NASDAQ:ETNB), has sold shares worth approximately $71,149, according to a recent SEC filing. The transaction comes as the stock ...
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...
89bio Provides Business Update and Outlook for 2025
Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second ...
Yahoo Finance5d
89bio, Inc. (ETNB)
In this article, we are going to take a look at where 89bio, Inc. (NASDAQ:ETNB) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of ...
89bio (NASDAQ:ETNB) Sets New 1-Year Low Following Insider Selling
Inc. (NASDAQ:ETNB – Get Free Report)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $5.99 and last traded at $6.09, with a ...
news.stocktradersdaily8d
How the (ETNB) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Investing21d
89bio's SWOT analysis: pegozafermin potential drives stock outlook
89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.
Nasdaq23d
89bio Provides Business Update and Outlook for 2025
CEO of 89bio. “We remain confident in pegozafermin’s potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale ...
Yahoo Finance15d
89bio, Inc. (ETNB)
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...